Zydus Cadila receives final approval from USFDA for Betamethasone Dipropionate Ointment

Zydus Cadila has received final approval from the USFDA to market Betamethasone Dipropionate Ointment USP, 0.05% (US RLD: Betamethasone Dipropionate Ointment).

Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). The ointment will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.353.7 as compared to the previous close of Rs. 358.2. The total number of shares traded during the day was 155853 in over 3041 trades.

The stock hit an intraday high of Rs. 361.95 and intraday low of 352.95. The net turnover during the day was Rs. 55691075.

Source : Equity Bulls

Keywords